Skip to main content
Clinical Trials/NCT04687410
NCT04687410UnknownNot Applicable

Randomized Comparison of Tissue Quality and Molecular Yield Between a Novel Crown-cut Biopsy Needle (FNB) and a Standard Aspiration Needle (FNA) for EUS Guided Diagnosis of Solid Pancreatic Lesions

Peter Vilmann MD, DSc, HC, FASGE2 sites in 1 country68 target enrollmentStarted: June 15, 2020Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
68
Locations
2
Primary Endpoint
Amount of tissue micro-fragments

Study Overview

Brief Summary

The aim of this study is to compare tissue quality and molecular yield between a novel crown-cut biopsy needle (FNB) and a standard aspiration needle (FNA) for EUS-guided diagnosis of solid pancreatic lesions.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Diagnostic
Masking
Double (Participant, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adult patients with a newly discovered SPL scheduled for EUS-guided tissue acquisition who can understand and provide a written consent.

Exclusion Criteria

  • Patients with uncorrected coagulopathies (INR >1.5 or platelet count <50,000) or patients treated with anticoagulants that cannot be discontinued.
  • Pregnant or lactating females.
  • Interposed, large vessels between the transducer and the target lesion.

Outcomes

Primary Outcomes

Amount of tissue micro-fragments

Time Frame: 1 month

Comparison of median number of tissue micro-fragments

Total tissue area

Time Frame: 1 month

Comparison of total total tissue area in um2

Diagnostic tissue area

Time Frame: 1 month

Comparison of total diagnostic tissue area in um2

Secondary Outcomes

  • Suitability for molecular analyses(6 months)
  • Diagnostic yield(1 month)
  • Diagnostic performance(12 month)
  • Mean DNA concentration(6 months)
  • Adverse event rate(1 month)

Investigators

Sponsor
Peter Vilmann MD, DSc, HC, FASGE
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Peter Vilmann MD, DSc, HC, FASGE

Professor

Herlev Hospital

Study Sites (2)

Loading locations...

Similar Trials